Two drugs used in the treatment of several cancers have poorly understood drug-drug interactions that could have significant implications for patients.
Digging Deeper into Agent Orange, Genomic Alterations and Prostate Cancer
The defoliant known as Agent Orange has been linked to a wide range of malignancies since the conclusion of the Vietnam War, including prostate cancer.
Does Age, Treatment Selection Drive Differences in ALL Outcomes?
Acute lymphoblastic (or lymphocytic) leukemia (ALL) occurs more often in children than in adults and has much better outcomes in youngsters.
Surprise! Short-term ADT Might Benefit Cognition in Prostate Cancer Patients
In an unexpected turn of events, a team including investigators with the Naval Medical Center in Portsmouth, VA., found that adding short-term androgen deprivation therapy (STADT) to prostate bed salvage radiotherapy not only reduced progression in advanced prostate cancer but also improved patients’ mental processing speed.
Real-World Study Shows Veterans with NSCLC Benefit from Durvalumab
The continuing conundrum of clinical trials is how to assess their applicability to the patients actually seen in practice.
Obesity/Weight Gain Associated with MGUS Progression to Multiple Myeloma
Obesity ranks high in the list of risk factors for the development of monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM).
Walter Reed Researchers Tackle Issues with Real-World Data on Multiple Myeloma
Real-world data holds the promise of enabling a better understanding of how medications work in the type of patients typically seen in clinics and hospitals.
Combination Therapy Outperforms ADT Alone in Metastatic Prostate Cancer
Studies have shown improved survival in patients who receive either docetaxel or androgen signaling agents (ASIs) such as abiraterone or enzalutamide in combination with androgen deprivation therapy.
VA’s Equal Access Care Mitigates Disparities in HCC Treatment, Outcomes
Rising rates of hepatocellular carcinoma (HCC) have focused attention on improving all aspects of the malignancy, from new methods of screening, earlier detection, more efficacious treatment, and extended survival. At the same time, the increased number of cases has made differences in access and outcomes more apparent.
Nivolumab Plus Cabozantinib Improves Health-related Quality of Life in RCC
At the 2023 American Society of Clinical Oncology (ASCO) annual meeting in Chicago a new analysis of data from the CheckMate 9ER trial was presented.
HER2 May Provide Therapeutic Target for Pancreatic Ductal Adenocarcinoma
PDAC accounts for 90% of all pancreatic cancers, which have an overall five-year survival rate of just 12%.
VA Demonstrates Success in Remote Treatment of Aggressive Cancers
Initially, the TeleOncology service managed oral therapies and watchful waiting and surveillance of veterans with cancer, but it has expanded to offer remote supervision for intravenous cancer treatments.